Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Onivyde Nanoliposomal Irinotecan Cancelled
Onpattro patisiran Polyneuropathy in hereditary transthyretin-mediated amyloidosis Reimburse with clinical criteria and/or conditions Complete
Onsolis Fentanyl Citrate Pain, breakthrough cancer pain Withdrawn
Onsolis Fentanyl Citrate Pain, breakthrough cancer pain Do not list Complete
Onstryv safinamide Parkinson's disease Do not reimburse Complete
Onureg azacitidine Acute myeloid leukemia Reimburse with clinical criteria and/or conditions Complete
Opdivo nivolumab Stage IIB or IIC melanoma, adjuvant Reimburse with clinical criteria and/or conditions Active
Opdivo nivolumab Urothelial carcinoma Reimburse with clinical criteria and/or conditions Complete
Opdivo Nivolumab Melanoma Adjuvant Therapy Reimburse with clinical criteria and/or conditions Complete
Opdivo nivolumab Esophageal or gastroesophageal junction cancer Reimburse with clinical criteria and/or conditions Complete
Opdivo nivolumab Gastroesophageal junction or esophageal adenocarcinoma Reimburse with clinical criteria and/or conditions Complete
Opdivo Nivolumab classical Hodgkin Lymphoma (cHL) after failure of ASCT Reimburse with clinical criteria and/or conditions Complete
Opdivo Nivolumab Metastatic Hepatocellular Carcinoma (HCC) Do not reimburse Complete
Opdivo nivolumab Resectable Non-Small Cell Lung Cancer Reimburse with clinical criteria and/or conditions Complete
Opdivo Nivolumab Metastatic non small cell lung cancer Reimburse with clinical criteria and/or conditions Complete
Opdivo Nivolumab Metastatic Renal Cell Carcinoma Reimburse with clinical criteria and/or conditions Complete
Opdivo Nivolumab Squamous Cell Carcinoma of Head and Neck (SCCHN) Reimburse with clinical criteria and/or conditions Complete
Opdivo Nivolumab Metastatic Melanoma Reimburse with clinical criteria and/or conditions Complete
Opdivo & Yervoy in combo Nivolumab & Ipilimumab in combo Metastatic Melanoma Reimburse with clinical criteria and/or conditions Complete
Opdivo in combination with Yervoy Nivolumab in combination with Ipilimumab Advanced or Metastatic Renal Cell Carcinoma (RCC). Reimburse with clinical criteria and/or conditions Complete
Opdivo in combination with Yervoy Nivolumab in combination with Ipilimumab NSCLC Reimburse with clinical criteria and/or conditions Complete
Opdivo-Yervoy nivolumab-ipilimumab Malignant Pleural Mesothelioma (MPM) Reimburse with clinical criteria and/or conditions Complete
Opdualag nivolumab and relatlimab unresectable or metastatic melanoma Reimburse with clinical criteria and/or conditions Complete
Opsumit Macitentan Pulmonary arterial hypertension List with clinical criteria and/or conditions Complete
Opsynvi macitentan and tadalafil Pulmonary arterial hypertension Reimburse with clinical criteria and/or conditions Complete